What's Happening?
The World Health Organization (WHO) is advocating for the adoption of adaptive trial designs, similar to those used for COVID-19 mRNA vaccines, to facilitate the safe and timely inclusion of pregnant and lactating women in vaccine clinical trials. This
approach involves starting trials with healthy, non-pregnant adults and then expanding to include pregnant women once initial safety and immunogenicity data are reassuring. Predefined safety milestones are used to trigger staged inclusion, often beginning with participants in their second and third trimesters. Concurrently, large observational pregnancy registries capture real-world safety data from women vaccinated outside of trials. Frequent interim analyses allow for rapid protocol adjustments, and harmonized maternal, fetal, and infant endpoints enable pooled analyses. This strategy aims to address the historical exclusion of these populations from early trial phases, which often delays access to potentially life-saving vaccines.
Why It's Important?
The historical exclusion of pregnant and lactating women from vaccine clinical trials has led to significant data gaps regarding vaccine safety and efficacy in these vulnerable populations. This often results in delayed access to vaccines, leaving them unprotected during outbreaks or against endemic diseases. By adopting adaptive trial designs, the WHO aims to accelerate the generation of crucial data, enabling informed policy decisions and ensuring that these women can benefit from vaccine advancements without undue delay. This approach is particularly vital for vaccines targeting diseases like malaria, tuberculosis, and meningococcus, where maternal vaccination could offer protection to both the mother and the infant through placental antibody transfer. The ability to align immunological endpoints and bridge data across populations will enhance the understanding of vaccine performance and safety in pregnancy, ultimately improving maternal and infant health outcomes globally.
What's Next?
The WHO's recommendations suggest that future vaccine development programs should plan for the early inclusion of pregnant women, defining clear 'go/no-go' criteria for expansion and including lactating women as part of the expanded population. This will involve leveraging incidental pregnancy exposures for safety monitoring and aligning immunological endpoints to bridge data across populations. Trimester-stratified enrollment will be critical to understand how maternal physiology and fetal development affect vaccine performance and safety throughout gestation. For specific vaccines, such as those for Group B Streptococcus (GBS), trials will need to consider optimal timing for vaccination to maximize placental antibody transfer. Similarly, for meningococcal vaccines, trials incorporating trimester-stratified enrollment, especially in high-transmission regions, could inform maternal vaccine policy. Observational studies will continue to play a crucial role alongside randomized controlled trials, providing valuable real-world evidence on safety and pregnancy outcomes, particularly for groups often excluded from early trial phases.
Beyond the Headlines
The push for adaptive trial designs for pregnant and lactating women reflects a broader ethical and public health imperative to ensure equitable access to medical advancements. Historically, these populations have been excluded due to concerns about fetal and infant safety, leading to a lack of evidence-based guidance for healthcare providers and mothers. This new approach signifies a shift towards proactive inclusion, recognizing the unique physiological changes during pregnancy and lactation and the potential benefits of vaccination for both mother and child. It also highlights the need for robust pharmacovigilance systems and regulatory frameworks that can adapt to evolving scientific understanding. The successful implementation of these adaptive designs could set a precedent for the inclusion of other vulnerable populations in clinical research, fostering a more inclusive and responsive medical research ecosystem.
